Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Oncology Letters
|
November 1, 2017
The role of LIM and SH3 protein-1 in bladder cancer metastasis
Misaki Sato, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Biochemical and Biophysical Research Communications
|
May 7, 2022
TMEM2 expression is downregulated as bladder cancer invades the muscle layer
Mihoko Sutoh Yoneyama, Tohru Yoneyama, Yuki Tobisawa, et al.
European Journal of Cell Biology
|
May 10, 2014
Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis
Mihoko Sutoh Yoneyama, Shingo Hatakeyama, Tomonori Habuchi, et al.
IJU Case Reports
|
May 5, 2022
Renal metastasis of ovarian granulosa cell tumor
Kyo Togashi, Tohru Yoneyama, Mihoko Sutoh Yoneyama, et al.
The Prostate
|
July 7, 2025
Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer
Kai Ozaki, Tohru Yoneyama, Yuka Kubota, et al.
World Journal of Urology
|
March 6, 2021
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer
Yuka Kubota, Shingo Hatakeyama, Tohru Yoneyama, et al.
Molecular Medicine Reports
|
February 20, 2014
Extravasation during bladder cancer metastasis requires cortactin‑mediated invadopodia formation
Noriko Tokui, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Molecular Medicine Reports
|
April 5, 2014
Invadopodia are essential in transurothelial invasion during the muscle invasion of bladder cancer cells
Kengo Imanishi, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
The Journal of Urology
|
March 23, 2011
Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells
Hayato Yamamoto, Mihoko Sutoh, Shingo Hatakeyama, et al.
Molecular Medicine Reports
|
November 21, 2012
Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity
Teppei Okamoto, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Oncology Letters
|
November 1, 2017
The role of LIM and SH3 protein-1 in bladder cancer metastasis
Misaki Sato, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Biochemical and Biophysical Research Communications
|
May 7, 2022
TMEM2 expression is downregulated as bladder cancer invades the muscle layer
Mihoko Sutoh Yoneyama, Tohru Yoneyama, Yuki Tobisawa, et al.
European Journal of Cell Biology
|
May 10, 2014
Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis
Mihoko Sutoh Yoneyama, Shingo Hatakeyama, Tomonori Habuchi, et al.
IJU Case Reports
|
May 5, 2022
Renal metastasis of ovarian granulosa cell tumor
Kyo Togashi, Tohru Yoneyama, Mihoko Sutoh Yoneyama, et al.
The Prostate
|
July 7, 2025
Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer
Kai Ozaki, Tohru Yoneyama, Yuka Kubota, et al.
World Journal of Urology
|
March 6, 2021
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer
Yuka Kubota, Shingo Hatakeyama, Tohru Yoneyama, et al.
Molecular Medicine Reports
|
February 20, 2014
Extravasation during bladder cancer metastasis requires cortactin‑mediated invadopodia formation
Noriko Tokui, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Molecular Medicine Reports
|
April 5, 2014
Invadopodia are essential in transurothelial invasion during the muscle invasion of bladder cancer cells
Kengo Imanishi, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
The Journal of Urology
|
March 23, 2011
Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells
Hayato Yamamoto, Mihoko Sutoh, Shingo Hatakeyama, et al.
Molecular Medicine Reports
|
November 21, 2012
Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity
Teppei Okamoto, Mihoko Sutoh Yoneyama, Shingo Hatakeyama, et al.
Page
of 3